CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen receptor (CAR) T cell therapy for non-Hodgkins lymphoma and in whom have had a sub-optimal response early on to CAR T-cell therapy. Immunotherapy with CC-99282 may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may

Trial Details

NCT ID

NCT06209619

Phase

PHASE1

Sponsor

Nathan Denlinger

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Biopsy
Biospecimen Collection
Computed Tomography
Golcadomide
Positron Emission Tomography
Rituximab

Locations (sample)

Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

Written informed consent obtained to participate in the study and Health Insurance Portability and Accountability Act (HIPAA) authorization for rel…
Age ≥ 18 years at the time of consent
Diagnosis of B-cell Non-Hodgkin's lymphoma including either large B-cell lymphoma or follicular lymphoma. Large B-cell subtypes include but are not…
Eastern Cooperative Oncology Group (ECOG) Score = 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →